---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-251394"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2026-06-01T20:05:16+00:00"
generated_at: "2026-06-01T20:13:54.906241+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

## Summary
- Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
- FDA cited secondary malignancy risk from another PRC2 inhibitor (Tazverik) withdrawn March 2026.
- Company will explore strategic alternatives (merger, acquisition, etc.) and reduce operating expenses.
- Held $333.3M in cash, cash equivalents, and marketable securities as of March 31, 2026.

## SEC filing metadata
- accession: 0001193125-26-251394
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2026-06-01T20:05:16+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-251394
- JSON: https://secwatch.observer/filing/0001193125-26-251394.json
- Plain text: https://secwatch.observer/filing/0001193125-26-251394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.